Source: Financial Supervisory Service Data Analysis, Retrieval and Transfer System (DART) / 2026-04-24
Disclosure Type: Major Business Matters Related to Investment Decisions (Amendment)
💡 3-Second Summary
Celltrion has lifted its disclosure deferral regarding the global Phase 3 clinical trial protocol amendment for Keytruda biosimilar candidate CT-P51, officially disclosing the previously withheld target sample size of 220 patients.
📊 1. [Key Disclosure Details & Major Figures Summary]
- Investigational Product & Reference Drug: CT-P51 (Reference Product: Keytruda)
- Indication: Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Clinical Trial Phase: Global Phase 3 Trial Protocol Amendment Filing
- Amendment Details & Rectified Metric:
- Reason for Amendment: Lifting of the disclosure deferral as the protocol amendment approval milestone was reached.
- Number of Clinical Trial Subjects: (Before) Confidential ➡️ (After) 220 patients
- Trial Application Information:
- Filing Date (Fact Confirmation): March 30, 2026 (The date the amendment application was submitted to the MFDS)
- Regulatory Authority: South Korea Ministry of Food and Drug Safety (MFDS)
- Protocol Specifications:
- Treatment Duration: 2 years of treatment
- Trial Design: Randomized, double-blind, active-controlled, parallel-group, Phase 3 clinical trial
- Clinical Trial Registration Number: EU CT number 2024-514048-98-00
- Note: This is an administrative amendment updating a previously restricted section from the initial March 30, 2026 filing. The official text does not state the underlying corporate strategy for the initial confidentiality or whether any other structural parameters within the protocol were altered.
📈 2. [Expert Perspective: What This Means for Investors]
- Disclosure of Withheld Administrative Metrics: This filing serves as objective confirmation that the quantitative figure regarding patient enrollment (220 patients), which was kept confidential under “management confidentiality,” has been made public in accordance with regulatory timeline requirements. Investors now have access to the exact target sample size for this modified trial.
- No Inherent Implication on Clinical Outcomes: The publication of this figure is a purely technical reconciliation of an unreleased data field. It does not imply any positive or negative operational shift in development speed or trial efficacy. Market participants should avoid formulating speculative assumptions regarding other potential modifications since the filing remains silent on those details.
- Awareness of Statistical Development Risks: As outlined in the standard warning within the document, the statistical probability of an investigational drug successfully navigating to final marketing authorization is approximately 10%. Investors must remain mindful that unforeseen clinical outcomes or regulatory hurdles during this 2-year Phase 3 evaluation could still disrupt or alter commercialization goals.
📝 Editor’s Comment (by K-STOCK Editor)
This amended filing presents the technical data point that the target sample size for Celltrion’s Keytruda biosimilar (CT-P51) protocol amendment is set at 220 patients. Because the official regulatory document does not outline the operational background of the initial deferral or describe any broader changes to the clinical design, readers should look strictly at the factual metrics provided. The objective course of action is to track the progress of the 2-year treatment schedule for these 220 patients, avoiding speculative predictions regarding commercialization timelines until official interim or final trial results are disclosed.
📢 Disclaimer & Sources
Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
